Circulation of Rift Valley Fever Virus Antibody in Cattle during Inter-Epizootic/Epidemic Periods in Selected Regions of Tanzania.

Tanzania is one of the sub-Saharan countries that have experienced a number of Rift Valley fever (RVF) outbreaks at intervals of 10-20 years since the first isolation of the virus during the early 1930s. Recent studies have reported serological evidence of inter epizootic/epidemic period circulation of RVF virus (RVFV) in livestock and humans. The aim of this study was to conduct a cross-sectional survey in Tanzania during 2015/16 to further explore the possibility that RVFV was circulating among cattle during the Inter epizootic/epidemic period. A total of 443 cattle samples were collected in Manyara, Dodoma, Singida, and Mbeya regions of Tanzania. The samples were tested for RVFV antibodies using a commercial ELISA kit and a plaque reduction neutralization test. Serum samples were also tested for RVFV viral RNA by an reverse transcription polymerase chain reaction (RT-PCR) assay. An overall RVFV seroprevalence rate of 7.7% (34/443) was detected by ELISA among cattle in all four regions. The Mbeya region cattle had the highest seroprevalence of 26.4% (23/87), followed by Dodoma 5.9% (10/171) and lastly Singida 0.9% (1/101). Of 33 ELISA antibody-positive samples, only 0.2% (1/443) had IgM antibody. Of 36 ELISA antibody-positive and doubtful samples, 32 were positive for neutralizing antibody with titers between 10 and > 10,240. None of the samples were positive for RVFV viral RNA by RT-PCR. The detection of RVFV antibodies in cattle suggested that these animals were involved in an enzootic cycle during the interepidemic period and that the high antibody titers may confer protection of cattle against RVFV.

The impact of anthelmintic drugs on weight gain of smallholder goats in subtropical regions.

Helminth infections are recognised as a major impediment to the productivity of goats in smallholder production systems. We used a multilevel framework to estimate the impact that administration of locally available anthelminthic drugs can have on the weight gains of goats in smallholder settings in India and Tanzania. We recruited 234 goats from 92 households from Odisha state in India and 253 goats from 15 households from Dodoma region in Tanzania. The goats were non-pregnant adult females, and from each household a minimum of two goats were recruited wherever possible. Each goat was randomly assigned to treatment with a locally available anthelminthic drug, or non-treatment. Each animal was tagged, weighed and had its body condition score (BCS) assessed. Animals were followed up after 28 and 56 days and re-weighed. To account for the local variations in exposure to helminths and for variations between households and herds, the data were analysed in a multilevel mixed model with herd in village as nested random effects. Over the 56 days of study, the non-treated goats in India had gained a mean of 30.64 g per day (a daily gain of 0.23% baseline body weight) and in Tanzania 66.01 g per day (0.33% baseline body weight). From the mixed model, the treated goats in India gained a mean of 25.22 g per day more than non-treated goats, this is significantly greater than the weight gain in non-treated goats (p < 0.001). In Tanzania treated goats gained a mean of 9.878 g per day more than non-treated goats, which is also significantly greater than non-treated goats (p = 0.007). Furthermore, in India and Tanzania, goats with a lighter weight at the baseline survey gained greater amounts of weight. In both studies the BCS of the treated goats improved by a greater amount than the non-treated goats. In this study we have demonstrated that in certain settings, the administration of anthelminthic drugs has a clear beneficial impact on goat weight.

Serological evidence of inter-epizootic/inter-epidemic circulation of Rift Valley fever virus in domestic cattle in Kyela and Morogoro, Tanzania.

BACKGROUND: Tanzania is among the Rift Valley fever (RVF) epizootic/endemic countries in sub Saharan Africa, where RVF disease outbreaks occur within a range of 3 to 17-year intervals. Detection of Rift Valley fever virus (RVFV) antibodies in animals in regions with no previous history of outbreaks raises the question of whether the disease is overlooked due to lack-of effective surveillance systems, or if there are strains of RVFV with low pathogenicity. Furthermore, which vertebrate hosts are involved in the inter-epidemic and inter-epizootic maintenance of RVFV? In our study region, the Kyela and Morogoro districts in Tanzania, no previous RVF outbreaks have been reported. METHODOLOGY: The study was conducted from June 2014 to October 2015 in the Kyela and Morogoro districts, Tanzania. Samples (n = 356) were retrieved from both the local breed of zebu cattle (Bos indicus) and Bos indicus/Bos Taurus cross breed. RVFV antibodies were analyzed by two enzyme-linked immunosorbent assay (ELISA) approaches. Initially, samples were analyzed by a RVFV multi-species competition ELISA (cELISA), which detected both RVFV IgG and IgM antibodies. All serum samples that were positive with the cELISA method were specifically analysed for the presence of RVFV IgM antibodies to trace recent infection. A plaque reduction neutralization assay (PRNT80) was performed to determine presence of RVFV neutralizing antibodies in all cELISA positive samples. FINDINGS: Overall RVFV seroprevalence rate in cattle by cELISA in both districts was 29.2% (104 of 356) with seroprevalence rates of 33% (47/147) in the Kyela district and 27% (57/209) in the Morogoro district. In total, 8.4% (30/356) of all cattle sampled had RVFV IgM antibodies, indicating current disease transmission. When segregated by districts, the IgM antibody seroprevalence was 2.0% (3/147) and 12.9% (27/209) in Kyela and Morogoro districts respectively. When the 104 cELISA positive samples were analyzed by PRNT80 to confirm that RVFV-specific antibodies were present, the majority (89%, 93/104) had RVFV neutralising antibodies. CONCLUSION: The results provided evidence of widespread prevalence of RVFV antibody among cattle during an inter-epizootic/inter-epidemic period in Tanzania in regions with no previous history of outbreaks. There is a need for further investigations of RVFV maintenance and transmission in vertebrates and vectors during the long inter-epizootic/inter-epidemic periods.